Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 26.69 USD 0.91% Market Closed
Market Cap: 19.8B USD

EV/EBITDA
Enterprise Value to EBITDA

-92.1
Current
-30.7
Median
5.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-92.1
=
Enterprise Value
19.4B USD
/
EBITDA
-210.9m USD
EBITDA Growth EV/EBITDA to Growth
US
Summit Therapeutics Inc
NASDAQ:SMMT
Average EV/EBITDA: 16.3
Negative Multiple: -92.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 568.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.8
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.4
17%
1.2
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -460.6 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.2 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-65.9
2-Years Forward
EV/EBITDA
-48.4
3-Years Forward
EV/EBITDA
-38.8